CDXS Codexis, Inc.
USHealthcareAs of 2026-07-10 16:00
Why CDXS matters now
Codexis, Inc. (CDXS) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.43 with -5.08% on the session and $220.9M in market capitalization; recent performance reads 1-month +4.47% and YTD +57.67%.
The latest financial table shown here is Q1 2026, with revenue of $15.2M, net income of $-8.7M, and EPS of $-0.10. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.5%.
The latest indexable market news headline is "Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $5.00; recent insider activity includes De Vre Raymond filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.40
P/S
2.99
EV/EBITDA
-12.22
DCF Value
$-3.47
FCF Yield
-9.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
83.9%
Operating Margin
-33.2%
Net Margin
-41.0%
ROE
-68.1%
ROA
-24.7%
ROIC
-22.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.2M | $-8.7M | $-0.10 |
| Q4 2025 | $38.9M | $9.6M | $0.11 |
| FY 2025 | $70.4M | $-44.0M | $-0.50 |
| Q3 2025 | $8.6M | $-19.6M | $-0.22 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$5.00 - $5.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.48
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.